Robert-Bosch-Krankenhaus

PRDM16 expression is an independent prognostic factor in AML with the double-mutant NPM1/FLT3-ITD genotype (2026) Stasik S, Eckardt JN, Röllig C, Baldus CD, Serve H, Müller-Tidow C, Schäfer-Eckart K, et al. Journal article Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy (2026) Dendorfer SM, Schmidt-Brücken K, Kramer M, Steffen B, Schliemann C, Mikesch JH, Alakel N, et al. Journal article Correction: Association between the 400-m walk test and sensor-based daily physical activity in frail and sarcopenic older adults (European Geriatric Medicine, (2025), 16, 5, (1799-1810), 10.1007/s41999-025-01262-4) (2026) Rogler J, Krumpoch S, Freiberger E, Lindemann U, Kob R Journal article, Erratum Walking into aging: real-world mobility patterns and digital benchmarks from the InCHIANTI Study (2025) Albites-Sanabria J, Palumbo P, Bandinelli S, D’Ascanio I, Mellone S, Paraschiv-Ionescu A, Küderle A, et al. Journal article Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia (2025) Ruhnke L, Bill M, Zukunft S, Eckardt JN, Schäfer S, Stasik S, Hanoun M, et al. Journal article Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer (2025) Hoeppner J, Brunner T, Schmoor C, Bronsert P, Kulemann B, Claus R, Utzolino S, et al. Journal article Fatigue, Polyuria, and Hidden Uveitis: A Case of Tubulointerstitial Nephritis and Uveitis Syndrome Diagnosed in Primary Care. (2025) Kerner M, Todoroff J, von Schnakenburg C, Amann KU, Müller-Kühnle J Journal article Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial (2025) Stelljes M, Middeke JM, Bug G, Wagner-Drouet EM, Müller LP, Schmid C, Krause S, et al. Journal article Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis (2025) Ronnacker J, Muller PJ, Mikesch JH, Zukunft S, Weinbergerová B, Šrámek J, Valka J, et al. Journal article VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AML (2025) Kretschmer L, Ruhnke L, Schliemann C, Fransecky L, Steffen B, Kaufmann M, Burchert A, et al. Journal article